Skip to main content

Table 3 Parameters for estimation of ADR incidence from both active and passive surveillance, January 2004 to December 2005

From: Adverse drug events resulting from use of drugs with sulphonamide-containing anti-malarials and artemisinin-based ingredients: findings on incidence and household costs from three districts with routine demographic surveillance systems in rural Tanzania

 

RUFIJI District

KILOMBERO/ ULANGA Districts

Probable ADR events detected by passive surveillance:

SP monotherapy

7

13

Artesunate monotherapy

0

0

Combination of AS/SP

3

0

Total

10

13

Probable ADR events detected by active surveillance:

SP monotherapy

2

7

Artesunate monotherapy

0

0

Combination of AS/SP

2

0

Total

4

7

Total probable ADR events detected:

SP monotherapy

9

20

Artesunate monotherapy

0

0

Combination of AS/SP

5

0

Total

14

20

Total Population Under DSS Surveillance

84,500

74,200

Estimates of average annual anti-malarial drug exposure rates in the DSS areas per capita:

    SP monotherapy

0.46

0.54

    Artesnuate monotherapy

0.37

0

    Combination of AS/SP

0.53

0

Estimate of total doses used by the DSS population in 2004/5 (population * average annual exposure)

    SP monotherapy

38,870

40,068

    AS monotherapy

31,265

0

    Combination of AS/SP

44,785

0

Estimated ADR incidence per 100,000 exposures 1

    SP monotherapy

11.6

25.0

    AS monotherapy

0

-

    Combination of AS/SP

5.6

-

  1. 1Calculated as (Number of “probable” ADR cases / estimated total doses used) * 0.5 (multiplied by 0.5 to annualize ADR occurrence rates since our data cover a two year period).